New drugs: will they solve the problem of resistance to antibiotics?

A large body of data points to the growing rate of resistance, especially in Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacteriaceae, with Klebsiella pneumoniae as the notorious 'collector’ of new resistance mechanisms.

0
1047

Despite a large arsenal of usually effective antibiotics, the therapeutic options are few in cases of infections caused by multidrug-resistant (MDR) organisms, and even more so by extensively drug-resistant (XDR) strains, often leaving only colistin as reliable option. Reports of pan-drug resistance, for which no antibiotic options exist, are accumulating in some parts of the world. The production of carbapenemases together with other resistance mechanisms, including those to unrelated antibiotic groups, has hampered the usefulness of carbapenems as the therapy of choice for extended-spectrum b-lactamase producing MDR Gram-negative bacteria.

Author: U. Theuretzbacher. Center for Anti-Infective Agents, Vienna, Austria

Clinical Microbiology and Infection 23 (2017) 695e696

Download full PDF.